Aesthetics & Cosmeceuticals

The safety profile of dupilumab is similar to those observed in shorter-term studies, according to data presented at SDPA Annual Fall Dermatology Conference.

Results from a five-year analysis suggested that long-term dupilumab for the treatment of moderate-to-severe atopic dermatitis (AD) in adults is safe and consistent with other placebo-controlled trial...

Brian Kirk is Sentient’s new Chief Marketing Officer (CMO), and Jennifer Redmond joins as Chief Revenue Officer (CRO).

Brian Kirk is Sentient’s new Chief Marketing Officer (CMO), and Jennifer Redmond joins as Chief Revenue Officer (CRO).  Mr. Kirk is charged with elevating Sentient's marketing investment to support Ti...

BoNT/E is a novel botulinum neurotoxin serotype E characterized by a rapid onset of action as early as 8 hours after administration and short duration of effect within 2-3 weeks.

Allergan Aesthetics’ trenibotulinumtoxinE (BoNT/E) performed well for the treatment of moderate to severe glabellar lines, according to topline results from two pivotal Phase 3 studies. 

BoNT/E is a ...

Sciton Inc. is expanding their mJOULE system to include ClearV and ClearSilk.

Sciton Inc. is expanding their mJOULE system to include ClearV and ClearSilk to treat vascular lesions and skin discoloration.

"The combination of 1064 in the ClearV and ClearSilk delivery systems wi...

Mr. Hauser will be responsible for commercial performance in existing international markets, expansion into new geographies, and the international launch of AviClear in 2024. 

Brent Hauser is the new President, International, at Cutera, Inc.

Mr. Hauser will report directly to Taylor Harris, Cutera’s Chief Executive Officer, and will be responsible for commercial performanc...

Journey Medical granted Maruho an exclusive license to develop and commercialize Qbrexza (Rapifort DRM04 / glycopyrronium tosylate hydrate) for the treatment of hyperhidrosis, in South Korea, Taiwan, Hong Kong, Macau, Thailand, Indonesia, Malaysia, Philippines, Singapore, Vietnam, Brunei, Cambodia, ...

Journey Medical Corporation has entered into an exclusive license agreement with Maruho Co., Ltd. for Qbrexza in South Korea and Other Asian Nations.

Maruho Co., Ltd. is Journey’s exclusive licensing...